Cost-effectiveness of Lecanemab for the Treatment of Early Alzheimer's Disease: A Canadian Societal Perspective

Early Clinical Outcomes following Lecanemab Therapy for Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease

Degree of Adherence to Brain Health Recommendations in Patients Pursuing Anti-Amyloid Antibody Therapy for Alzheimer’s Disease

The Importance of Early Recognition and Treatment Initiation for Managing Alzheimer's disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial